First in Human Study of SNV1521 With a RAS Inhibitor for People With Advanced Pancreatic Cancer

This study is a Phase 1 clinical trial testing an oral investigational drug called SNV1521 together with a RAS-targeted cancer medicine in people with pancreatic cancer that cannot be removed by surgery or has spread. The main goals are to find doses of the drug combination that are safe and tolerable and to look for early signs that the treatment may help control the cancer. Participants will receive the study medicines in repeating cycles and will have regular blood tests, scans, and other exams to monitor side effects and how their cancer responds.

Trial Details

NCT ID
NCT07756281
Phase
PHASE1
Sponsor
ParVation Therapeutics, Inc.
Status
RECRUITING
Cancer Type
Pancreatic Cancer
Interventions
  • SNV1521
  • daraxonrasib
Locations (sample)
  • Houston, Texas, United States|29.76328,-95.36327

Key Eligibility Criteria

  • Adults (18 years and older).
  • Diagnosis of pancreatic cancer that cannot be removed by surgery or has spread to other parts of the body.
  • Cancer confirmed by tissue or cell examination (histology or cytology).
  • At least one measurable tumor on scans.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Cancer Trials on Trialify →